Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEOPLE: Open-label Follow-up Study of the PEPITES Study to Evaluate the Long-term Efficacy and Safety of Viaskin Peanut
2016-002916-42Phase 3Terminated
- Sponsor
- DBV Technologies
- Start
- Dec 2016
- Modality
- Transdermal Patches → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of DBV712 Viaskin® in peanut allergy, sponsored by DBV Technologies. Primary endpoint: Long-term desensitization rate at 3 years. Started Dec 2016; status: terminated.
02
Drugs
DBV712 Viaskin®
03
Conditions
peanut allergy
Beyond the preview
Go deeper on 2016-002916-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002916-42.